FENNEC PHARMACEUTICALS INC. (FENC) research
FENNEC PHARMACEUTICALS INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $10.91
- As of
FENNEC PHARMACEUTICALS INC. (FENC): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-17.
As of . Source: SEC EDGAR filings for FENC. Method and limitations.
Share the FENC intelligence card
See FENC live in the terminal
Track FENC's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live FENC terminal, freeActive signals for FENC
- highCONSENSUS_BUY
3 tracked funds increased FENC this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased FENC this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +165% to FENC (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +571% to FENC (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 50% of FENC (2026Q2)
FREE, NO ACCOUNT
Every signal on FENC, as it fires
You are seeing 5 of 24 signals recorded on FENC since 2026-06-10.
The five above landed across 2 days. The other 19 were recorded on 2 other days. 15 of the 24 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FENC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 31447P100 · 2026Q2 | $1.4M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 31447P100 · 2026Q2 | $764K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 31447P100 · 2026Q2 | $649K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 31447P100 · 2026Q2 | $606K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 31447P100 · 2026Q2 | $283K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FENC
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
FENC mentioned in Kresmion daily briefs
FENC against its peers
FENC's operating margin of -14.1% ranks in the 88th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | FENC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 44.6M USD | 33.5M USD | 72 | 15 |
| Operating margin | -14.1% | -284.0% | 88 | 12 |
| Net margin | -21.8% | -258.8% | 88 | 12 |
| Return on equity | -27.5% | -63.0% | 88 | 20 |
Peers (23): BBOT, EVMN, BNTC, PRLD, PROK, MYGN, LRMR, RCKT, DMAC, OBIO, OCGN, GALT, XFOR, ENTA, TTRX, CCCC, ARCT, EBS, ARTV, LXEO, ZURA, CMPX, EDIT. Left out: RZLT (no annual filing), PRTC (period gap). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (FENC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more FENC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to FENCand get the insider, 13F, options, and confluence read in one view.